Literature DB >> 1907291

Determination of glibenclamide and its two major metabolites in human serum and urine by column liquid chromatography.

T Rydberg1, E Wåhlin-Boll, A Melander.   

Abstract

A simple reversed-phase liquid chromatographic method for the measurement of low concentrations of glibenclamide (glyburide) and its two major metabolites, 4-trans- and 3-cis-hydroxyglibenclamide, in human serum and urine has been developed. The compounds were extracted with n-hexane-dichloromethane (1:1). The UV detection wavelength was 203 nm. The minimum detectable serum level of glibenclamide was 1 ng ml (2 nM), and the relative standard deviation was 8.9% (n = 9). When maximum sensitivity was desired the metabolites were chromatographed separately. Metabolites in urine were measured by the same method after five-fold sample dilution. The utility of the method was tested on a healthy volunteer who ingested 3.5 mg of glibenclamide. The parent drug was present in the serum for at least 18 h, and the metabolites in the urine for at least 24 h.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907291     DOI: 10.1016/0378-4347(91)80084-p

Source DB:  PubMed          Journal:  J Chromatogr


  8 in total

1.  Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia.

Authors:  A Holstein; A Plaschke; C Hammer; E-H Egberts
Journal:  Eur J Clin Pharmacol       Date:  2003-04-16       Impact factor: 2.953

Review 2.  Is there a concentration-effect relationship for sulphonylureas?

Authors:  A Melander; R Donnelly; T Rydberg
Journal:  Clin Pharmacokinet       Date:  1998-03       Impact factor: 6.447

3.  Validation of a sensitive LC-MS assay for quantification of glyburide and its metabolite 4-transhydroxy glyburide in plasma and urine: an OPRU Network study.

Authors:  Suresh Babu Naraharisetti; Brian J Kirby; Mary F Hebert; Thomas R Easterling; Jashvant D Unadkat
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-10-22       Impact factor: 3.205

4.  Hormonal counterregulation and consecutive glimepiride serum concentrations during severe hypoglycaemia associated with glimepiride therapy.

Authors:  A Holstein; A Plaschke; C Hammer; M Ptak; J Kuhn; C Kratzsch; J Diekmann; K Kleesiek; H H Maurer; E-H Egberts
Journal:  Eur J Clin Pharmacol       Date:  2003-11-22       Impact factor: 2.953

5.  Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma.

Authors:  A Sener; A G Akkan; W J Malaisse
Journal:  Acta Diabetol       Date:  1995-03       Impact factor: 4.280

6.  Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide.

Authors:  Olga L Zharikova; Valentina M Fokina; Tatiana N Nanovskaya; Ronald A Hill; Donald R Mattison; Gary D V Hankins; Mahmoud S Ahmed
Journal:  Biochem Pharmacol       Date:  2009-08-11       Impact factor: 5.858

7.  Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model.

Authors:  Steve Choy; Emilie Hénin; Jan-Stefan van der Walt; Maria C Kjellsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-11-24       Impact factor: 2.745

Review 8.  Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity.

Authors:  Lucy Darakjian; Malavika Deodhar; Jacques Turgeon; Veronique Michaud
Journal:  Int J Mol Sci       Date:  2021-05-07       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.